Drugs / Ultrix
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 2/3 | NCT05308212 Comparator | Mar → Jul 2021 | influenza | St. Petersburg Research Institute of Vaccines and Sera | Completed | No outcome recorded |
| Phase 3 | NCT05317767 Comparator | Feb → Jul 2020 | influenza | St. Petersburg Research Institute of Vaccines and Sera | Completed | No outcome recorded |
| Phase 3 | NCT05457894 Comparator | Jan 2020 → Mar 2021 | influenza | St. Petersburg Research Institute of Vaccines and Sera | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ultrix | “Double-blind, Comparative, Randomized Tolerability, Safety and Immunogenicity Trial of Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Vaccine in Children Aged 6...” NCT05317767 ↗ |
| Known as | Ultrix vaccine | “Comparative assessment of the tolerability, safety, and immunogenicity of the FLU-M® Tetra quadrivalent inactivated split influenza vaccine and the Ultrix® vaccine in...” NCT05308212 ↗ |
| Modality | Vaccine | “inactivated split influenza vaccine” NCT05308212 ↗ |
| Route | Intramuscular | “solution for intramuscular injection” NCT05308212 ↗ |